Showing 40,321 - 40,340 results of 101,733 for search '(( 5 fold decrease ) OR ( 5 ((point decrease) OR (((a decrease) OR (mean decrease)))) ))', query time: 1.65s Refine Results
  1. 40321
  2. 40322

    Predicted performance of a control program administered to dogs on arrival in US animal shelters. by Benjamin D. Dalziel (650353)

    Published 2014
    “…(<b>B</b>) Decreasing control efficacy to 75% can still achieve eradication in isolated shelters (blue region, solid line), however shelters that transfer dogs amongst themselves at the observed mean rate of τ = 0.1 would preserve CIV in a few shelters despite the vaccination program (red region, dashed line). …”
  3. 40323

    Optimal Dose and Method of Administration of Intravenous Insulin in the Management of Emergency Hyperkalemia: A Systematic Review by Ziv Harel (2696983)

    Published 2016
    “…There was no statistically significant difference in mean decrease in serum potassium (K<sup>+</sup>) concentration at 60 minutes between studies in which insulin was administered as an infusion of 20 units over 60 minutes and studies in which 10 units of insulin was administered as a bolus (0.79±0.25 mmol/L versus 0.78±0.25 mmol/L, <i>P</i> = 0.98) or studies in which 10 units of insulin was administered as an infusion (0.79±0.25 mmol/L versus 0.39±0.09 mmol/L, <i>P</i> = 0.1). …”
  4. 40324

    An idealized view of the opportunity provided by a comparative and integrated oncology drug development path. by Ira Gordon (369869)

    Published 2013
    “…Factoring in additional costs for comparative studies with this approach of US$150,000 for studies conducted in the preclinical setting, US$250,000 for studies conducted before or during Phases I–II human trials and US$1 million for studies conducted before Phases II–III studies, the total cost of development is estimated at US$2.07 billion. The result may be a decrease in average clinical trial costs per approved drug from US$290 million to US$173 million <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1000161#pmed.1000161-Adams1" target="_blank">[5]</a>.…”
  5. 40325
  6. 40326

    Diabetes, Drug Treatment and Mortality in COVID-19: A Multinational Retrospective Cohort Study by Jennifer E. Nyland (11412878)

    Published 2021
    “…Use of DPP-4 inhibitors was associated with a reduction in respiratory complications (24.0% vs 29.2%; RR, 0.82 [95% CI, 0.74-0.90]; <i>P</i> <.001), and continued use of DPP-4 inhibitors after hospitalization was associated with a decrease in mortality compared with those who discontinued use (9% vs 19%; RR, 0.45 [95% CI, 0.28-0.72]; <i>P</i> <.001). …”
  7. 40327

    Data_Sheet_1_Expression of vitamin D receptor, CYP24A1, and CYP27B1 in normal and inflamed canine pancreases.DOCX by Dohee Lee (432106)

    Published 2023
    “…This study showed that VDR expression decreased in inflamed pancreases and demonstrated CYP24A1 and CYP27B1 expression in the canine pancreas for the first time. …”
  8. 40328
  9. 40329

    High-Resolution Recombination Patterns in a Region of Human Chromosome 21 Measured by Sperm Typing by Irene Tiemann-Boege (34093)

    Published 2006
    “…Detailed study of one of the new hot spots revealed a sperm donor with a decrease in recombination intensity at the canonical recombination site but an increase in crossover activity nearby. …”
  10. 40330

    Cyclin-dependent kinase inhibitor flavopiridol promotes remyelination in a cuprizone induced demyelination model by Guiyun Mi (835541)

    Published 2016
    “…In the first experiment of this study, we examined the expression of cell cycle related genes in brains of mice following CPZ administration for 5 weeks by means of microarray assay. In addition, we performed a double labeling of BrdU and Ki-67 to calculate cell cycle exit index in the mice. …”
  11. 40331
  12. 40332
  13. 40333
  14. 40334

    (A and B) Pyrene-actin assay using the vesicle-free fraction of rat kidney papillae extracts by Yumi Noda (52675)

    Published 2011
    “…(A) Actin depolymerization was monitored by the decrease in pyrene fluorescence and normalized to the initial fluorescence value in each experiment. …”
  15. 40335

    An HIV-1 Envelope Immunogen with W427S Mutation in CD4 Binding Site Induced More T Follicular Helper Memory Cells and Reduced Non-Specific Antibody Responses by Hao-Tong Yu (697936)

    Published 2014
    “…We constructed a gp120 mutant W427S of an HIV-1 primary R5 strain and examined its ability in the elicitation of Ab and the production of Tfh by immunization of BALB/c mice. …”
  16. 40336
  17. 40337
  18. 40338
  19. 40339
  20. 40340